Gabapentin for acute and chronic pain

Wiffen, Philip J; McQuay, Henry J; Edwards, Jayne E; Moore, R Andrew

doi:10.1002/14651858.cd005452

Cited by 182 publications

(168 citation statements)

References 37 publications

Supporting

Mentioning

151

Contrasting

Unclassified

Order By: Relevance

“…The links between the two mechanisms may be inhibitory, with acute pain inhibiting chronic pain (Baliki, Geha, Fields, & Apkarian, 2010). Further, different therapies relieve the two forms of pain (e.g., Chou & Huffman, 2007;Wiffen, McQuay, Edwards, & Moore, 2005).…”

Section: Discussionmentioning

confidence: 99%

Visual Distortion of Body Size Modulates Pain Perception

et al. 2011

View full text Add to dashboard Cite

Pain is a complex subjective experience, that can be shaped by several cognitive, psychological and even contextual variables. For example, simply viewing the body reduces the reported intensity of acute physical pain. We investigated whether this visually induced analgesia can be modulated by the visually depicted size of the stimulated body part. We measured contact heat-pain thresholds, while participants viewed either their own hand or a neutral object, at real size, enlarged, or reduced. Vision of the body was analgesic, increasing heat-pain thresholds by ~ 4°C. Importantly, enlargement of the viewed hand enhanced this analgesia, while looking at a reduced hand decreased it. These results demonstrate that visual distortions of body size modulate sensory components of pain, and reveal a clear functional relation between the perception of pain and the representation of the body.3

show abstract

Section: Discussionmentioning

confidence: 99%

Visual Distortion of Body Size Modulates Pain Perception

et al. 2011

View full text Add to dashboard Cite

show abstract

“…16,26,27 The AAN guidelines for painful DPN recommend pregabalin (level A) because of the availability of strong evidence and gabapentin (level B evidence). 20 A systematic review by Danish pain experts 17 and several Cochrane reviews 32,35,67 confirm the efficacy of these α 2 δ-ligands for the treatment of NeuP.…”

Section: Guidelinementioning

confidence: 93%

Clinical practice guidelines for management of neuropathic pain: Expert panel recommendations for South Africa

Chetty

Baalbergen²,

Bhigjee

et al. 2012

S Afr Med J

View full text Add to dashboard Cite

“…4,6 The absence of CBZ efficacy in some patients, cases of intolerance, 7 hypersensitivity, fluid retention, 8 drug interactions, a narrower therapeutic index and a higher degree of adverse side effects than recent drugs like gabapentin (GBP) has led to a progressively increased use of the latter drug in several neuropathic pain syndromes. [9][10][11][12] GBP has been used alone 13 or in association with CBZ or iamotrigine 14 and results in pain reduction in at least 47% of TN patients. However, it should be noted that the effectiveness of GBP and other drugs like Surprisingly, although the association of analgesics with different mechanisms of action may putatively result in analgesia potentiation and less adverse side effects, the possibility for associating drug therapies has been explored very little until present.…”

mentioning

confidence: 99%

Gabapentin Supplemented With Ropivacain Block of Trigger Points Improves Pain Control and Quality of Life in Trigeminal Neuralgia Patients When Compared With Gabapentin Alone

Lemos¹,

Flores²,

Oliveira

et al. 2008

The Clinical Journal of Pain

View full text Add to dashboard Cite

Objective: Pain control in trigeminal neuralgia (TN) is achieved using anticonvulsivants, mainly carbamazepine. When this drug cannot be used, other drugs like gabapentin (GBP) have been used to provide adequate pain control. To improve the therapeutic effect of GBP, we evaluated the clinical efficacy of associating GBP with ropivacain (ROP) analgesic block of facial trigger points in TN patients.Design: Thirty-six TN patients were randomly assigned during 4 weeks to 1 of the following protocols: Protocol I-daily oral GBP administered in a titrated dose; Protocol II-ROP applied as analgesic block to TN trigger points once a week; Protocol III-daily oral GBP plus ROP once a week. Protocol II had to be discontinued in 7/12 patients owing to insufficient pain control. Pain intensity was evaluated by the Visual Analog Scale (VAS) and disability was assessed by Sickness Impact Profile.Results: When compared with Protocol I, Protocol III (GBP+ROP) patients showed (1) a reduction of VAS score after 7 and 28 days of treatment, an effect that was still present 6 and 12 months later; (2) a faster reduction of VAS score using a significantly lower dose of GBP; (3) a smaller total and daily GBP dose at the end of the treatment, which resulted in a total absence of adverse side effects; and (4) an improvement of the functional well-being measured by the Sickness Impact Profile. The number needed to treat (NNT) (GBP+ROP vs. GBP protocols) to obtain 1 GBP+ROP-treated patient with at least 50% pain relief was 1.71 (day 7) and 2.40 (day 28). Conclusions:The association of GBP and ROP is safe, without side effects and results in an important clinical benefit associated to an improvement of the functional health status of TN patients when compared with GBP alone. This may constitute a therapeutic alternative for pain control in TN patients who cannot be treated with carbamazepine.

show abstract

Gabapentin for acute and chronic pain

Cited by 182 publications

References 37 publications

Visual Distortion of Body Size Modulates Pain Perception

Visual Distortion of Body Size Modulates Pain Perception

Clinical practice guidelines for management of neuropathic pain: Expert panel recommendations for South Africa

Gabapentin Supplemented With Ropivacain Block of Trigger Points Improves Pain Control and Quality of Life in Trigeminal Neuralgia Patients When Compared With Gabapentin Alone

Contact Info

Product

Resources

About